QIAGEN announced it has entered into a definitive agreement to acquire Parse Biosciences, a pioneer in scalable, instrument-free single-cell sequencing solutions, marking a major...
QIAGEN and GENCURIX, a leading molecular diagnostics company, announced a strategic collaboration to co-develop advanced oncology assays for the QIAcuityDx platform-a next-generation digital PCR system...
QIAGEN announced the launch of two new tools for designing and ordering custom solutions that can be used to support microbial analysis of bacterial,...
QIAGEN and Myriad Genetics announced they will develop a globally distributable kit-based test for analyzing Homologous Recombination Deficiency (HRD) status. This next-generation sequencing (NGS)...
